Launch offer: 7 days freeLaunch offer: 7-day free trial for investors and Research Analysts.

Start free trial
Close
NIFTY 50

Divi's Laboratories share price

Divi's Laboratories Ltd. · NSE: DIVISLAB · Healthcare

₹8,950.00 −212.00 −2.31%
Nifty 100Nifty 500Nifty PharmaF&O · lot 100Large cap
Last session · 23 Oct 2026, 16:08 IST

Price, one year

1 year agoLow 5,821.00 · High 9,624.00Latest close
1W−0.89%
1M−4.30%
3M+22.52%
6M+42.39%
1Y+36.41%

Price range

Open
₹9,165.00
High
₹9,175.50
Low
₹8,797.00
Previous close
₹9,162.00
Volume
6.2 L
Market cap
₹2,37,594 Cr
Day range
52-week range

Key statistics

Results to 30 Jun 2026 · Consolidated
P/E (TTM)
81.2
Price to book
14.2
Return on equity
17.4%
EPS (TTM)
₹110.21
Book value / share
₹631.37
Debt to equity
0.00
Revenue (TTM)
₹11,230 Cr
Net profit (TTM)
₹2,925 Cr
Sales growth, YoY
+27.8%
Profit growth, YoY
+65.5%
Operating margin
35.3%
Net margin
26.1%
Sales CAGR, 3 years
+10.8%
Profit CAGR, 3 years
+12.1%
Promoter holding
51.88%
Promoter shares pledged
0.00%
From the company's results filed with NSE; TTM is the last four quarters. Ratios use the latest price.

Shareholding pattern

% of shares
HolderSep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters51.8951.8851.8851.8851.88
Foreign institutions19.3920.0820.2920.2020.38
Domestic institutions19.7619.2819.2219.3819.17
Mutual funds13.9913.7313.4213.8714.66
Retail and others6.786.606.476.416.55

Futures and options

23 Oct 2026
Lot size
100
Put-call ratio (OI)
0.63
Max pain
₹9,300.00
Highest call OI strike
9,500.00
Highest put OI strike
8,300.00
ATM implied volatility
34.4% IV rank 84
Futures basis
−0.52%
Rollover
61.4%

Futures open interest, last sessions

DateBuild-upPriceOI change
23 OctShort buildup−2.44%+1.29%
22 OctLong buildup+0.28%+0.08%
21 OctShort buildup−0.01%+0.80%
19 OctShort buildup−0.54%+0.39%
16 OctLong buildup+1.11%+1.23%

Option figures are for the 27 Oct 2026 expiry.

Results and announcements

Latest results (quarter to 30 Jun 2026) filed 1 Aug 2026. results: 7 Nov 2026.

Exchange filings as published on NSE; routine filings are left out.

Peers in Healthcare

All Healthcare stocks
CompanyPriceChangeMarket capP/E
Sun Pharmaceutical IndustriesSUNPHARMA ₹1,748.00 −0.57% ₹4,19,404 Cr 34.7
Torrent PharmaceuticalsTORNTPHARM ₹4,524.40 −1.97% ₹1,72,094 Cr 76.4
Zydus LifesciencesZYDUSLIFE ₹1,129.40 −0.49% ₹1,12,658 Cr 25.2
Apollo Hospitals EnterpriseAPOLLOHOSP ₹7,730.00 +1.65% ₹1,11,146 Cr 53.2
CiplaCIPLA ₹1,338.00 +0.53% ₹1,08,093 Cr 32.1
Laurus LabsLAURUSLABS ₹1,970.00 −1.62% ₹1,06,442 Cr 97.2
Dr. Reddy's LaboratoriesDRREDDY ₹1,229.50 −0.77% ₹1,02,624 Cr 36.6
Mankind PharmaMANKIND ₹2,212.60 −2.77% ₹91,390 Cr 44.7
Aurobindo PharmaAUROPHARMA ₹1,571.70 −2.43% ₹90,432 Cr 24.6
LupinLUPIN ₹1,928.90 +0.36% ₹88,207 Cr 15.9

Frequently asked questions

What is the share price of Divi's Laboratories today?

Divi's Laboratories (NSE: DIVISLAB) was at ₹8,950.00 on 23 Oct 2026, a change of −2.31% from the previous close.

What are the 52-week high and low of Divi's Laboratories?

Over the last 52 weeks Divi's Laboratories traded between ₹5,647.50 and ₹9,740.00 (daily highs and lows on NSE on 23 Oct 2026).

What is the market capitalisation of Divi's Laboratories?

About ₹2,37,594 Cr at the latest price, with a P/E of 81.2, a price-to-book of 14.2, a return on equity of 17.4%. Ratios use the company's latest reported results.

Who owns Divi's Laboratories shares?

According to the shareholding pattern filed with the exchange at the end of the quarter to 30 Sep 2026, promoters held 51.88%, foreign institutions 20.38%, domestic institutions 19.17%.

Is Divi's Laboratories traded in futures and options?

Yes, DIVISLAB is in NSE's futures and options segment. The lot size is 100 shares.

Which sector and indices does Divi's Laboratories belong to?

NSE classifies Divi's Laboratories under Healthcare; it is a member of Nifty 100, Nifty 500.

Follow Divi's Laboratories with research you can verify. Add it to a watchlist, see screens and charts, and get calls from SEBI-registered research analysts with recorded track records.

Start free trial